Billings Clinic
Especially For:

Clinical Trials

Title   Breast Cancer: Adjuvant Chemotherapy HER2/Neu Positive Primary Breast Cancer
Description   CTSU N063D ALTTO: A Randomized, Multi-Center, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer.
IRB Number   CTSU N063D ALTTO
Category   Breast Cancer
Inclusion/Notes   Adjuvant Treatment, HER2/Neu Positive.
Status   Active
Start Date   03/14/2008
Principal Investigator (PI)   Jorge Nieva, MD
Contact Name   Joan Koch, RN
Contact Email   jkoch@billingsclinic.org
Phone   (406) 435-7481
Alternate Phone   (406) 435-7480
Fax   (406) 435-7489
Funding Source   NCI
Print This Page
Email to a Friend
Home | Contact | Site Map | Site Privacy Policy | Terms & Conditions | Patient Privacy Policy | Medical Records | Fast Command
2800 10th Ave. North | P.O. Box 37000 | Billings, Montana 59107 | 406.238.2500
© Copyright 2014 Billings Clinic. All Rights Reserved.